BOCOM INTL: Maintains a "buy" rating on Strong Healthcare (02595) with a target price of HK$58.

BOCOM INTL released a research report stating that the investment rating and target price of GenFos Pharmaceuticals (02595) are maintained at "buy" and 51 Hong Kong dollars, respectively. The bank stated that the overseas clinical and collaboration progress of the KRAS G12D inhibitor is ideal. BOCOM INTL believes that excellent overseas preliminary data provide further evidence for the best potential of VS7375 in its class. Verastem will reveal more efficacy data from the TARGET-D 101 study in 2H26. It is recommended to focus on this. Other key catalysts overseas include: 1) completion of enrollment in the TARGET-D 101 pancreatic cancer and NSCLC monotherapy cohorts and CRC combination cohorts (end of June); 2) discussion with the FDA on the design of the first-line Phase III study (end of 2026) and initiation of enrollment (first half of 2027).